Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics

被引：22

作者：

Appel H. ^{[1
]}

Sieper J. ^{[1
]}

机构：

[1] Department of Gastroenterology, Infectiology, and Rheumatology, Charité Berlin, Campus Benjamin Franklin, 12200 Berlin

来源：

Current Rheumatology Reports | 2008年 / 10卷 / 5期

关键词：

Bone Formation; Ankylose Spon; Spondylitis; Bone Marrow Edema; Zygapophyseal Joint;

D O I：

10.1007/s11926-008-0058-x

中图分类号：

学科分类号：

摘要：

Ankylosing spondylitis (AS) is characterized by two key pathologic findings: sacroiliac joint and spinal inflammation and new bone formation with possible bone fusion, usually in the axial skeleton. Thus, structural damage in AS must be viewed differently than that in rheumatoid arthritis. Tumor necrosis factor blockers effectively inhibit inflammation, as shown by signs and symptoms, function, C-reactive protein, and MRI, and will probably prevent erosive structural damage. However, the ossification of already-damaged bone cannot be influenced by tumor necrosis factor blockade, because these drugs do not inhibit osteoblasts. It remains to be seen whether additional targeting of new bone formation is clinically meaningful in advanced AS. The most important action to prevent structural damage is probably an early diagnosis and effective anti-inflammatory treatment of AS. © Springer Science+Business Media, LLC 2008.

引用

页码：356 / 363

页数：7

共 69 条

[1]

Sieper J., Rudwaleit M., Khan M.A., Braun J., Concepts and epidemiology of spondyloarthritis, Best Pract Res Clin Rheumatol, 20, pp. 401-417, (2006)

[2]

Braun J., Sieper J., Ankylosing spondylitis, Lancet, 369, pp. 1379-1390, (2007)

[3]

Rudwaleit M., Metter A., Listing J., Et al., Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria, Arthritis Rheum, 54, pp. 569-578, (2006)

[4]

van der Linden S.M., Valkenburg H.A., de Jongh B.M., Cats A., The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population, Arthritis Rheum, 27, pp. 241-249, (1984)

[5]

Rudwaleit M., Khan M.A., Sieper J., The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria?, Arthritis Rheum, 52, pp. 1000-1008, (2005)

[6]

Feldtkeller E., Khan M.A., van der Heijde D., Et al., Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis, Rheumatol Int, 23, pp. 61-66, (2003)

[7]

Brandt H.C., Spiller I., Song I.H., Et al., Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis, Ann Rheum Dis, 66, pp. 1479-1484, (2007)

[8]

Song I.H., Poddubnyy D.A., Rudwaleit M., Sieper J., Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs, Arthritis Rheum, 58, pp. 929-938, (2008)

[9]

Braun J., Brandt J., Listing J., Et al., Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial, Lancet, 359, pp. 1187-1193, (2002)

[10]

Davis Jr. J.C., Van Der Heijde D., Braun J., Et al., Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial, Arthritis Rheum, 48, pp. 3230-3236, (2003)

← 1 2 3 4 5 6 7 →